Render Target: STATIC
Render Timestamp: 2024-11-22T11:45:54.534Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-05-10 06:27:09.884
Product last modified at: 2024-05-30T07:06:14.929Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

Asparagine Synthetase (E6C2C) XP® Rabbit mAb (PE Conjugate) #31211

Filter:
  • F

    Supporting Data

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa)
    Source/Isotype Rabbit IgG
    Application Key:
    • F-Flow Cytometry 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Description

    This Cell Signaling Technology antibody is conjugated to phycoerythrin (PE) and tested in-house for direct flow cytometric analysis in human cells. This antibody is expected to exhibit the same species cross-reactivity as the unconjugated Asparagine Synthetase (E6C2C) XP® Rabbit mAb #92479.

    Product Usage Information

    Application Dilution
    Flow Cytometry (Fixed/Permeabilized) 1:50

    Storage

    Supplied in PBS (pH 7.2), less than 0.1% sodium azide and 2 mg/ml BSA. Store at 4°C. Do not aliquot the antibody. Protect from light. Do not freeze.

    Protocol

    Specificity / Sensitivity

    Asparagine Synthetase (E6C2C) XP® Rabbit mAb (PE Conjugate) recognizes endogenous levels of total asparagine synthetase protein.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly473 of human asparagine synthetase protein.

    Background

    Asparagine synthetase (ASNS) catalyzes the synthesis of asparagine from aspartate and glutamine. Research studies have shown that intracellular asparagine can suppress apoptosis in a large number of human tumors. In addition, ASNS expression levels have been associated with the progression of gliomas and neuroblastomas in patients (1). Furthermore, acute lymphocytic leukemia cells frequently depend upon serum asparagine for their viability, as they lack ASNS (2). Deprivation of asparagine by L-asparaginase has therefore been developed as a therapeutic treatment for acute lymphocytic leukemia (2,3). In subsets of gastric and hepatic cancers, ASNS promoter hypermethylation correlates with low ASNS expression, sensitizing these cancers to the asparaginase treatment (4).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.